JP2023018678A5 - - Google Patents

Download PDF

Info

Publication number
JP2023018678A5
JP2023018678A5 JP2022119632A JP2022119632A JP2023018678A5 JP 2023018678 A5 JP2023018678 A5 JP 2023018678A5 JP 2022119632 A JP2022119632 A JP 2022119632A JP 2022119632 A JP2022119632 A JP 2022119632A JP 2023018678 A5 JP2023018678 A5 JP 2023018678A5
Authority
JP
Japan
Prior art keywords
seq
cdr
amino acid
acid sequence
set forth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022119632A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023018678A (ja
JP7638935B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2023018678A publication Critical patent/JP2023018678A/ja
Publication of JP2023018678A5 publication Critical patent/JP2023018678A5/ja
Priority to JP2025023976A priority Critical patent/JP2025081477A/ja
Application granted granted Critical
Publication of JP7638935B2 publication Critical patent/JP7638935B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022119632A 2021-07-27 2022-07-27 抗ccr8抗体 Active JP7638935B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025023976A JP2025081477A (ja) 2021-07-27 2025-02-18 抗ccr8抗体

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163226118P 2021-07-27 2021-07-27
US63/226,118 2021-07-27

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025023976A Division JP2025081477A (ja) 2021-07-27 2025-02-18 抗ccr8抗体

Publications (3)

Publication Number Publication Date
JP2023018678A JP2023018678A (ja) 2023-02-08
JP2023018678A5 true JP2023018678A5 (https=) 2024-09-09
JP7638935B2 JP7638935B2 (ja) 2025-03-04

Family

ID=82898810

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022119632A Active JP7638935B2 (ja) 2021-07-27 2022-07-27 抗ccr8抗体
JP2025023976A Pending JP2025081477A (ja) 2021-07-27 2025-02-18 抗ccr8抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025023976A Pending JP2025081477A (ja) 2021-07-27 2025-02-18 抗ccr8抗体

Country Status (26)

Country Link
US (1) US11639393B2 (https=)
EP (2) EP4491635A3 (https=)
JP (2) JP7638935B2 (https=)
KR (2) KR20250135339A (https=)
CN (1) CN117425677A (https=)
AR (1) AR126578A1 (https=)
AU (1) AU2022317803A1 (https=)
BR (1) BR112023024837A2 (https=)
CA (1) CA3220121A1 (https=)
CO (1) CO2023015915A2 (https=)
DK (1) DK4214240T3 (https=)
ES (1) ES2995868T3 (https=)
FI (1) FI4214240T3 (https=)
HR (1) HRP20241561T1 (https=)
HU (1) HUE069018T2 (https=)
IL (2) IL307533B2 (https=)
LT (1) LT4214240T (https=)
MX (1) MX2023014154A (https=)
PL (1) PL4214240T3 (https=)
PT (1) PT4214240T (https=)
RS (1) RS66234B1 (https=)
SA (1) SA523451582B1 (https=)
SI (1) SI4214240T1 (https=)
SM (1) SMT202400483T1 (https=)
WO (1) WO2023010054A1 (https=)
ZA (1) ZA202309516B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20260017503A (ko) 2020-02-14 2026-02-05 길리애드 사이언시즈, 인코포레이티드 Ccr8에 결합하는 항체 및 융합 단백질, 및 이의 용도
EP4606385A1 (en) 2022-10-18 2025-08-27 Meiji Seika Pharma Co., Ltd. Therapeutic agent for t cell tumor
AR131786A1 (es) 2023-02-06 2025-04-30 Bayer Ag Combinación de anticuerpos ccr8 con inhibidores de dgk
JPWO2024248037A1 (https=) 2023-05-30 2024-12-05
AR134514A1 (es) 2023-12-01 2026-01-21 Gilead Sciences Inc Proteína de fusión anti-fap-ligera y uso de esta
WO2025145207A1 (en) 2023-12-29 2025-07-03 Bristol-Myers Squibb Company Combination therapy of kras inhibitor and treg-depleting agent
WO2025186043A1 (en) 2024-03-06 2025-09-12 Bayer Aktiengesellschaft Pharmaceutical formulation for anti-ccr8 antibodies
US20260056209A1 (en) 2024-06-14 2026-02-26 Gilead Sciences, Inc. Anti-ccr8 antibodies and uses thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
EP1810035A4 (en) 2004-11-10 2010-03-17 Macrogenics Inc GENERATION OF FC ANTIBODY REGIONS FOR EFFECTOR FUNCTION
US10087259B1 (en) 2014-04-28 2018-10-02 Memorial Sloan Kettering Cancer Center Depleting tumor-specific tregs
JP7358047B2 (ja) 2016-05-16 2023-10-10 チェックマブ エス.アール.エル. 腫瘍浸潤制御性t細胞において選択的に脱制御されたマーカー
WO2018112033A1 (en) 2016-12-13 2018-06-21 President And Fellows Of Harvard College Methods and compositions for targeting tumor-infiltrating tregs
EP3616720B1 (en) * 2017-03-29 2021-02-17 Shionogi&Co., Ltd. Pharmaceutical composition for cancer treatment
CN113260381A (zh) * 2018-12-27 2021-08-13 盐野义制药株式会社 新型抗ccr8抗体
KR20250095745A (ko) * 2020-01-06 2025-06-26 백시넥스 인코포레이티드 항-ccr8 항체 및 이의 용도
KR20260017503A (ko) * 2020-02-14 2026-02-05 길리애드 사이언시즈, 인코포레이티드 Ccr8에 결합하는 항체 및 융합 단백질, 및 이의 용도
US20250019449A1 (en) 2020-03-05 2025-01-16 Memorial Sloan Kettering Cancer Center Anti-ccr8 agents
US20230119066A1 (en) 2020-03-23 2023-04-20 Bristol-Myers Squibb Company Anti-ccr8 antibodies for treating cancer
TW202216771A (zh) 2020-06-26 2022-05-01 德商拜耳廠股份有限公司 用於治療應用之ccr8抗體
WO2022003156A1 (en) 2020-07-02 2022-01-06 Oncurious Nv Ccr8 non-blocking binders
JP7610302B2 (ja) 2020-08-28 2025-01-08 ハーバー・バイオメド・(シャンハイ)・カンパニー・リミテッド Ccr8抗体及びその用途
CA3198456A1 (en) 2020-10-14 2022-04-21 Five Prime Therapeutics, Inc. Anti-c-c chemokine receptor 8 (ccr8) antibodies and methods of use thereof
CN115052892B (zh) 2020-10-16 2023-07-07 礼新医药科技(上海)有限公司 抗ccr8单克隆抗体及其用途
WO2022136647A1 (en) 2020-12-24 2022-06-30 Oncurious Nv Human ccr8 binders
EP4267618A1 (en) 2020-12-24 2023-11-01 Vib Vzw Non-blocking human ccr8 binders

Similar Documents

Publication Publication Date Title
JP2023018678A5 (https=)
JP2025081477A5 (https=)
JP2024045121A5 (https=)
JP2022177090A5 (https=)
JP2018108081A5 (https=)
JP2022061992A5 (https=)
JP2020023523A5 (https=)
JP2009225799A5 (https=)
JP2020524000A5 (https=)
JP2024086870A5 (https=)
HRP20190932T1 (hr) Molekule protutijela koje se vežu na il-17a i il-17f
JP2021524267A5 (https=)
FI4214240T3 (fi) Ccr8-vasta-aineita
JP2025032102A5 (https=)
JP2017052784A5 (https=)
JP2023081303A5 (https=)
RU2016119152A (ru) Стабильные и растворимые антитела, ингибирующие vegf
JP2024109911A5 (https=)
JP2023071956A5 (https=)
RU2011110169A (ru) Антитела против ccr2
JP2012525829A5 (https=)
JP2009539348A5 (https=)
JP2023093753A5 (https=)
JP2024105229A5 (https=)
JPWO2020059847A5 (https=)